GlobeNewsWire · ACR · November 8, 2026

Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases

Get the app for more

Explore stock news, insights and company research.